The numbers aren't "normal vs broken." The reference limits are the 5th percentile of men whose partners got pregnant within a year 1. Below the line you're in the slowest 5% of fertile men; conception still happens, it just takes longer on average.
The big-picture call beats any single line. Fertile and infertile men overlap heavily on every parameter 2. The test only sharpens when several values are low at once, or when one is dramatically off. One slightly low morphology number tells you almost nothing.
It doesn't measure function. Roughly 10–15% of male-factor cases involve sperm that look normal but don't fertilise correctly 3. A clean result lowers the odds male factor is the problem; it doesn't erase them.
The main cost isn't a bad result. It's the wasted year. By the time a typical couple hands him a cup, she's had blood work, ovarian-reserve testing, and an HSG over eighteen months while he's been checked for nothing. For a woman in her late thirties, that year is the difference between IUI and IVF, or her own eggs and donor eggs.
The other quiet cost is the testosterone clinic. Prescribed weekly shots for "low-T," a man can drop to zero sperm within months, because exogenous testosterone shuts off the brain signal the testes need 4. Recovery takes four to twelve months off the drug, sometimes incomplete. A baseline before treatment catches this early.
Book a CAP- or CLIA-accredited andrology lab through a urologist, fertility clinic, or GP; many take self-referral. Mail-in kits (Legacy, Fellow, Posterity) hold up against on-site testing when transport timing is honoured 5. Cheap home concentration-only tests are not a substitute.
Within-person variability runs 25–30% even in fertile men 6, which is why one sample is never a verdict.
A normal result quiets the plan. The female workup proceeds as the focus, IUI-versus-IVF decisions get made on her data without a "but we never checked him" overhang, and he steps back from the grind.
An abnormal result points somewhere specific. Paired with a hormone panel and a scrotal exam, low values sort into a short list of buckets: a varicocele worth repairing, a hormonal cause that responds to medication, an obstruction surgery can fix, or a finding that points to assisted reproduction 7. Each has a defined next step.
Even azoospermia has a path. A urologist orders genetic testing, and a retrieval procedure called microTESE recovers sperm directly from the testis for ICSI in about half of non-obstructive cases 7. Twelve months of unfocused trying becomes a plan.
The fine print — when to skip it, and what people get wrong
"Low numbers mean I'm infertile." No. Men have conceived with 0% strict-criteria morphology 8. "I have kids, so I'm fine." Weight, drugs, and age all move the numbers since.
Most wrong-looking results trace to a bad collection: incomplete sample, wrong transit temperature, off abstinence window, or an unreported fever. A man on testosterone reads as severely infertile; the fix is stopping the drug, not surgery 4.
A severely abnormal result links to higher all-cause mortality 9 and testicular cancer 10, so it earns a primary-care follow-up beyond the fertility clinic.
- 1WHO (2021). WHO Laboratory Manual for the Examination and Processing of Human Semen, sixth edition. link
- 2Guzick DS, Overstreet JW, Factor-Litvak P et al. (2001). Sperm morphology, motility, and concentration in fertile and infertile men. New England Journal of Medicine. link
- 3Patel AS, Leong JY, Ramasamy R (2018). Prediction of male infertility by the World Health Organization laboratory manual for assessment of semen analysis: a systematic review. Arab Journal of Urology. link
- 4Crosnoe LE, Grober E, Ohl D, Kim ED (2013). Exogenous testosterone: a preventable cause of male infertility. Translational Andrology and Urology. link
- 5Samplaski MK, Falk O, Honig S et al. (2019). Development and validation of a novel mail-in semen analysis system and the correlation between one hour and delayed semen analysis testing. Fertility and Sterility. link
- 6Schlegel PN, Sigman M, Collura B et al. (2021). Diagnosis and treatment of infertility in men: AUA/ASRM guideline part I. Fertility and Sterility. link
- 7Minhas S, Bettocchi C, Boeri L et al. (2023). European Association of Urology guidelines on male sexual and reproductive health: 2021 update on male infertility. European Urology. link
- 8Kovac JR, Smith RP, Cajipe M et al. (2017). Men with a complete absence of normal sperm morphology exhibit high rates of success without assisted reproduction. Asian Journal of Andrology. link
- 9Eisenberg ML, Li S, Behr B et al. (2014). Semen quality, infertility and mortality in the USA. Human Reproduction. link
- 10Hanson BM, Eisenberg ML, Hotaling JM (2018). Male infertility: a biomarker of individual and familial cancer risk. Fertility and Sterility. link
დაკავშირებული სახელმძღვანელოში (6)
- — Trying for a baby? Phthalate exposure tracks with poorer sperm measures, so cutting plasticizers is worth doing alongside the test.
- — If the analysis is abnormal, a palpable varicocele is one of the few correctable male-factor causes to look for.
- — Microplastics now turn up in human testes, and the fertility worry is one of the strongest reasons men cut plastic exposure.
- — If you're trying to conceive, overheating your testicles under heavy bedding all night can dent sperm production — go cooler and looser.
- — Both are quick testicular checks; a lump you find, or a history of one, can be why a semen result comes back low.
- — Starting TRT shuts down sperm production within weeks — bank a semen analysis first if fertility matters to you.
Baseline Semen Analysis
US cash price $50–$300; usually covered by insurance once an infertility diagnosis is coded. Mail-in DTC kits cost $130–$200. Trivial in the context of any subsequent fertility treatment.
One collection visit (private room at the lab) or a take-home protocol requiring delivery within 60 minutes at body temperature, plus 2–7 days of abstinence beforehand (WHO 2021). Repeat sample weeks later if abnormal. No needles, no fasting.
WHO Laboratory Manual now in its 6th edition (2021), with reference values empirically derived from 1,953 fertile fathers (Cooper et al. 2010). Universally recommended as the first male-factor test by AUA/ASRM (Schlegel et al. 2021), EAU (Minhas et al. 2023), and NICE.
Baseline data resolves a high-uncertainty question that often goes unanswered for months while a couple cycles through partner workup; clarity reduces anxiety and reorients the conception plan. Abnormal results can also be distressing, but the modal direction is informational relief and decision-making agency (AUA/ASRM 2021).
Identifies treatable medical conditions (varicocele, hypogonadotropic hypogonadism, hyperprolactinemia, thyroid disease, ejaculatory-duct obstruction) and surfaces iatrogenic harm from undisclosed exogenous androgen use (Crosnoe et al. 2013). Effect is downstream of acting on the result; the test itself changes nothing felt.
Severe oligospermia and azoospermia are weakly but consistently associated with elevated all-cause mortality and cancer risk (Eisenberg et al. 2014 HR ~2.3 with ≥2 abnormal parameters; Hanson et al. 2018). The signal supports systemic follow-up but the absolute effect for an individual is small.